#1 Clinical Trials Search in Europe

Mifamurtide

Mifamurtide, also known as MEPACT, is a drug being studied in clinical trials for the treatment of osteosarcoma, a type of bone cancer. These trials aim to evaluate the safety, efficacy, and potential benefits of mifamurtide when used alone or in combination with other treatments for patients with various stages of osteosarcoma. The studies focus on different aspects, including its use in newly diagnosed cases, metastatic disease, and as part of post-operative chemotherapy regimens.

Table of Contents

What is Mifamurtide?

Mifamurtide, also known by its brand name MEPACT, is a medication that has shown promise in treating a specific type of bone cancer[1]. It belongs to a class of drugs that stimulate the immune system, helping the body fight against cancer cells more effectively[2].

What Conditions Does Mifamurtide Treat?

Mifamurtide is primarily used to treat osteosarcoma, which is the most common type of bone cancer[1]. Osteosarcoma typically affects children, teenagers, and young adults. It usually develops in areas where bones are growing quickly, such as near the ends of long bones[2].

Specifically, mifamurtide is approved for use in:

  • High-grade resectable non-metastatic osteosarcoma in children, adolescents, and young adults[3]
  • It is used after the tumor has been surgically removed and in combination with chemotherapy[1]

Researchers are also studying its potential use in more advanced cases of osteosarcoma, including metastatic (cancer that has spread to other parts of the body) and recurrent (cancer that has come back after treatment) osteosarcoma[2].

How is Mifamurtide Administered?

Mifamurtide is given as an intravenous infusion, which means it’s delivered directly into the bloodstream through a vein. The typical treatment schedule is as follows:

  • The recommended dose is 2 mg/m² (milligrams per square meter of body surface area)[1]
  • It is usually given twice a week for the first 12 weeks, with at least 3 days between doses[3]
  • After the initial 12 weeks, it’s typically given once a week for an additional 24 weeks[3]
  • The total treatment duration is usually 36 weeks, with a total of 48 doses[3]

This schedule may vary depending on the specific treatment plan and the patient’s response to the medication.

Clinical Trials and Research

Several clinical trials are ongoing or have been conducted to evaluate the effectiveness of mifamurtide in different scenarios:

  • A study (NCT01194284) is looking at the safety and effectiveness of mifamurtide in newly diagnosed osteosarcoma patients[1]
  • Another trial (NCT02441309) is investigating mifamurtide alone or in combination with chemotherapy in patients with metastatic or recurrent osteosarcoma[2]
  • A study (NCT01459484) is examining how the expression of a specific protein (P-glycoprotein) might affect the treatment outcome when using mifamurtide[4]
  • A more recent trial (NCT03643133) is comparing post-operative chemotherapy alone versus chemotherapy combined with mifamurtide in high-risk osteosarcoma patients[5]

These studies aim to better understand how mifamurtide works, who it might benefit most, and how to use it most effectively.

Safety and Side Effects

As with any medication, mifamurtide can cause side effects. Common side effects may include:

  • Fever and chills
  • Fatigue
  • Nausea and vomiting
  • Headache
  • Muscle and joint pain

More serious side effects are possible but less common. The clinical trials are closely monitoring patients for any adverse events, especially those that are severe (grade 3 or higher)[2][3].

Future Prospects

Ongoing research is exploring several aspects of mifamurtide treatment:

  • Its effectiveness in different stages of osteosarcoma, including metastatic and recurrent cases[2]
  • How it interacts with different chemotherapy regimens[5]
  • Its impact on long-term survival and quality of life for patients[1][5]
  • Potential biomarkers that might predict which patients will respond best to the treatment[4]

These studies aim to optimize the use of mifamurtide and potentially expand its applications in cancer treatment.

Aspect Details
Drug Name Mifamurtide (MEPACT)
Type of Cancer Osteosarcoma (bone cancer)
Patient Population Children, adolescents, young adults, and adults up to 50 years old
Administration Intravenous infusion, typically 2 mg/m² twice weekly for 12 weeks, then weekly for 24 weeks
Treatment Combination Often combined with standard chemotherapy regimens
Primary Outcomes Event-free survival, overall survival, safety profile
Secondary Outcomes Progression-free survival, biological responses, quality of life
Trial Phases Phase II studies
Key Features Immune system activation, potential for improved outcomes in high-risk patients

FAQ

  • What is mifamurtide and how does it work? Mifamurtide is a drug that activates the immune system to help fight osteosarcoma. It works by stimulating certain immune cells, particularly macrophages, to attack cancer cells.
  • How is mifamurtide administered in clinical trials? In most trials, mifamurtide is given as an intravenous (IV) infusion. The typical dose is 2 mg/m² of body surface area, usually given twice a week for the first 12 weeks, then once a week for an additional 24 weeks.
  • What types of osteosarcoma patients are being studied in these trials? The trials include patients with various stages of osteosarcoma, including newly diagnosed cases, metastatic disease, and those with high-risk features. Some studies focus on children, adolescents, and young adults, while others include patients up to 50 years old.
  • Is mifamurtide used alone or with other treatments? Mifamurtide is often studied in combination with standard chemotherapy regimens. Some trials are comparing the effectiveness of chemotherapy alone versus chemotherapy plus mifamurtide.
  • What are the main outcomes being measured in these clinical trials? The primary outcomes typically include event-free survival, overall survival, and safety profiles. Secondary outcomes may include progression-free survival, biological responses, and quality of life measures.

Ongoing Clinical Trials on Mifamurtide

  • Study on Mifamurtide with Chemotherapy for Patients with High-Risk Osteosarcoma

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • A study comparing mifamurtide to sorafenib for treating high-risk osteosarcoma in children and young adults

    Not yet recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Poland

Glossary

  • Osteosarcoma: A type of bone cancer that typically develops in the bones of the arms, legs, or pelvis, most commonly affecting children, teenagers, and young adults.
  • Mifamurtide: A drug designed to activate the immune system, particularly macrophages, to help fight osteosarcoma. Also known by the brand name MEPACT.
  • Adjuvant therapy: Additional cancer treatment given after the primary treatment to lower the risk that the cancer will come back.
  • Metastatic: Cancer that has spread from its original site to other parts of the body.
  • Event-free survival: The length of time after treatment during which no specified events (such as disease recurrence or progression) are detected.
  • Overall survival: The length of time from either the date of diagnosis or the start of treatment that patients are still alive.
  • Progression-free survival: The length of time during and after treatment that a patient lives with the disease but it does not get worse.
  • RECIST criteria: Response Evaluation Criteria In Solid Tumors, a standard way to measure how well a cancer patient responds to treatment.
  • Pharmacodynamic: The study of the biochemical and physiological effects of drugs on the body.
  • Adverse event: Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure.

References

  1. https://clinicaltrials.gov/study/NCT01194284
  2. https://clinicaltrials.gov/study/NCT02441309
  3. https://clinicaltrials.gov/study/NCT00631631
  4. https://clinicaltrials.gov/study/NCT01459484
  5. https://clinicaltrials.eu/trial/study-on-mifamurtide-with-chemotherapy-for-patients-with-high-risk-osteosarcoma/